{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T13:00:30Z","timestamp":1784206830289,"version":"3.55.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T00:00:00Z","timestamp":1741996800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s13555-025-01382-6","type":"journal-article","created":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T07:10:28Z","timestamp":1742022628000},"page":"797-810","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Palmoplantar Pustulosis as an Immune-Mediated Inflammatory Disease with a Possible Relevance of Th17 Cell Plasticity: A Narrative Review"],"prefix":"10.1007","volume":"15","author":[{"given":"Tadashi","family":"Terui","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masamoto","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukari","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koremasa","family":"Hayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8657-0618","authenticated-orcid":false,"given":"Hideki","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,15]]},"reference":[{"key":"1382_CR1","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/bjd.17832","volume":"181","author":"YMF Andersen","year":"2019","unstructured":"Andersen YMF, Augustin M, Petersen J, et al. Characteristics and prevalence of plaque psoriasis in patients with palmoplantar pustulosis. Br J Dermatol. 2019;181:976\u201382.","journal-title":"Br J Dermatol"},{"key":"1382_CR2","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5070\/D3234034627","volume":"23","author":"D Wilsmann-Theis","year":"2017","unstructured":"Wilsmann-Theis D, Jacobi A, Frambach Y, et al. Palmoplantar pustulosis\u2014a cross-sectional analysis in Germany. Dermatol Online J. 2017;23:1.","journal-title":"Dermatol Online J"},{"key":"1382_CR3","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-006450","volume":"5","author":"K Kubota","year":"2015","unstructured":"Kubota K, Kamijima Y, Sato T, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ Open. 2015;5: e006450.","journal-title":"BMJ Open"},{"key":"1382_CR4","doi-asserted-by":"publisher","first-page":"62","DOI":"10.12703\/r\/10-62","volume":"10","author":"AMG Brunasso","year":"2021","unstructured":"Brunasso AMG, Massone C. Recent advances in palmoplantar pustulosis. Fac Rev. 2021;10:62.","journal-title":"Fac Rev"},{"key":"1382_CR5","first-page":"33","volume":"13","author":"K Heidemeyer","year":"2023","unstructured":"Heidemeyer K, Lee MM, Cazzaniga S, et al. Palmoplantar pustulosis: a systematic review of risk factors and therapies. Psoriasis (Auckland). 2023;13:33\u201358.","journal-title":"Psoriasis (Auckland)"},{"key":"1382_CR6","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1046\/j.1365-2133.1998.02113.x","volume":"138","author":"MO Ericksson","year":"1998","unstructured":"Ericksson MO, Hagforsen E, Lundin IP, Micha\u00eblsson G. Palmoplantar pustulosis: a clinical and immunohistological study. Br J Dermatol. 1998;138:390\u20138.","journal-title":"Br J Dermatol"},{"key":"1382_CR7","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1365-2133.2006.07725.x","volume":"156","author":"G Micha\u00eblsson","year":"2007","unstructured":"Micha\u00eblsson G, Kristj\u00e1nsson G, Lundin IP, Hagforsen E. Palmoplantar pustulosis and gluten sensitivity: a study of serum antibodies against gliadin and tissue transglutaminase, the duodenal mucosa and effects of gluten-free diet. Br J Dermatol. 2007;156:659\u201366.","journal-title":"Br J Dermatol"},{"key":"1382_CR8","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.jdermsci.2020.03.003","volume":"98","author":"M Murakami","year":"2020","unstructured":"Murakami M, Terui T. Palmoplantar pustulosis: Current understanding of disease definition and pathomechnism. J Dermatol Sci. 2020;98:13\u20139.","journal-title":"J Dermatol Sci"},{"key":"1382_CR9","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1111\/j.1365-2133.2010.09819.x","volume":"163","author":"E Hagforsen","year":"2010","unstructured":"Hagforsen E, Hedstrand H, Nyberg F, Micha\u00eblsson G. Novel findings of Langerhans cells and interleukin-17 expression in relation to the acrosyringium and pustule in palmoplantar pustulosis. Br J Dermatol. 2010;163:572\u20139.","journal-title":"Br J Dermatol"},{"key":"1382_CR10","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1046\/j.1523-1747.2003.12094.x","volume":"120","author":"K Asumalahti","year":"2013","unstructured":"Asumalahti K, Ameen M, Suomela S, et al. Genetic analysis of PSORS1 distinguishes guttate psoriasis and palmoplantar pustulosis. J Investig Dermatol. 2013;120:627\u201332.","journal-title":"J Investig Dermatol"},{"key":"1382_CR11","doi-asserted-by":"publisher","first-page":"2538","DOI":"10.1038\/jid.2015.186","volume":"135","author":"R M\u00f6ssner","year":"2015","unstructured":"M\u00f6ssner R, Frambach Y, Wilsmann-Theis D, et al. Palmoplantar pustular psoriasis is associated with missense variants in CARD14, but not with loss-of-function mutations in IL36RN in European patients. J Investig Dermatol. 2015;135:2538\u201341.","journal-title":"J Investig Dermatol"},{"key":"1382_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.jaci.2018.06.038","volume":"143","author":"S Twelves","year":"2019","unstructured":"Twelves S, Mostafa A, Dand N, et al. Clinical and genetic differences between pustular psoriasis subtypes. J Allergy Clin Immunol. 2019;143:1021\u20136.","journal-title":"J Allergy Clin Immunol"},{"key":"1382_CR13","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41590-022-01387-9","volume":"24","author":"A Schnell","year":"2023","unstructured":"Schnell A, Littman DR, Kuchroo VK. TH17 cell heterogeneity and its role in tissue inflammation. Nat Immunol. 2023;24:19\u201329.","journal-title":"Nat Immunol"},{"key":"1382_CR14","doi-asserted-by":"publisher","first-page":"6281.e23","DOI":"10.1016\/j.cell.2021.11.018","volume":"184","author":"A Schnell","year":"2021","unstructured":"Schnell A, Huang L, Singer M, et al. Stem-like intestinal Th17 cells give rise to pathogenic effector T cells during autoimmunity. Cell. 2021;184:6281.e23-98.e23.","journal-title":"Cell"},{"key":"1382_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/bjd.19560","volume":"184","author":"G Obeid","year":"2021","unstructured":"Obeid G, Do G, Kirby L, et al. Interventions for chronic palmoplantar pustulosis: abridged Cochrane systematic review and GRADE assessments. Br J Dermatol. 2021;184:1023\u201332.","journal-title":"Br J Dermatol"},{"key":"1382_CR16","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1111\/j.1600-0625.2011.01325.x","volume":"20","author":"M Murakami","year":"2011","unstructured":"Murakami M, Hagforsen E, Morhenn V, et al. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20:845\u20137.","journal-title":"Exp Dermatol"},{"key":"1382_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.coi.2017.07.007","volume":"49","author":"Y Liang","year":"2017","unstructured":"Liang Y, Sarkar MK, Tsoi LC, Gudjonsson JE. Psoriasis: a mixed autoimmune and autoinflammatory disease. Curr Opin Immunol. 2017;49:1\u20138.","journal-title":"Curr Opin Immunol"},{"key":"1382_CR18","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.jaad.2019.01.066","volume":"80","author":"U Mrowietz","year":"2019","unstructured":"Mrowietz U, Bachelez H, Burden AD, et al. Secukinumab for moderate-to-severe palmoplantar pustular psoriasis: results of the 2PRECISE study. J Am Acad Dermatol. 2019;80:1344\u201352.","journal-title":"J Am Acad Dermatol"},{"key":"1382_CR19","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s13555-023-01002-1","volume":"13","author":"AD Burden","year":"2023","unstructured":"Burden AD, Bissonnette R, Navarini AA, et al. Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase IIb, dose-finding study. Dermatol Ther (Heidelb). 2023;13:2279\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1382_CR20","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40257-023-00788-2","volume":"24","author":"T Terui","year":"2023","unstructured":"Terui T, Okubo Y, Kobayashi S, et al. Efficacy and safety of apremilast for the treatment of Japanese patients with palmoplantar pustulosis: results from a phase 2, randomized, placebo-controlled study. Am J Clin Dermatol. 2023;24:837\u201347.","journal-title":"Am J Clin Dermatol"},{"key":"1382_CR21","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.17659","author":"Y Okubo","year":"2025","unstructured":"Okubo Y, Murakami M, Kobayashi S, et al. Risankizumab in Japanese patients with moderate-to-severe palmoplantar pustulosis: Results from the randomized, phase 3 JumPPP study. J Dermatol. 2025. https:\/\/doi.org\/10.1111\/1346-8138.17659. (published online February 25, 2025).","journal-title":"J Dermatol"},{"issue":"5","key":"1382_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1007\/s40257-024-00876-x","volume":"25","author":"Y Okubo","year":"2024","unstructured":"Okubo Y, Kobayashi S, Murakami M, et al. Efficacy and safety of brodalumab, an anti-interleukin-17 receptor a monoclonal antibody, for palmoplantar pustulosis: 16-week results of a randomized clinical trial. Am J Clin Dermatol. 2024;25(5):837\u201347.","journal-title":"Am J Clin Dermatol"},{"key":"1382_CR23","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1002\/jvc2.73","volume":"2","author":"A Morita","year":"2023","unstructured":"Morita A, Chen Y, Leung MWL, et al. Effect of guselkumab on serum biomarkers in Japanese palmoplantar pustulosis patients in a randomized phase 3 study. JEADV Clin Pract. 2023;2:59\u201372.","journal-title":"JEADV Clin Pract"},{"key":"1382_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.jaad.2015.03.049","volume":"73","author":"K Papp","year":"2015","unstructured":"Papp K, Reich K, Leonardi CL, et al. Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: results of a Phase III, randomized, controlled trial (efficacy and safety trial evaluating the effects of apremilast in psoriasis [ESTEEM] 1). J Am Acad Dermatol. 2015;73:37\u201349.","journal-title":"J Am Acad Dermatol"},{"key":"1382_CR25","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1111\/bjd.14164","volume":"173","author":"C Paul","year":"2015","unstructured":"Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173:1387\u201399.","journal-title":"Br J Dermatol"},{"key":"1382_CR26","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.4049\/jimmunol.136.7.2348","volume":"136","author":"TR Mosmann","year":"1986","unstructured":"Mosmann TR, Cherwinski H, Bond MW, et al. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol. 1986;136:2348\u201357.","journal-title":"J Immunol"},{"key":"1382_CR27","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/383787a0","volume":"383","author":"AK Abbas","year":"1996","unstructured":"Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature. 1996;383:787\u201393.","journal-title":"Nature"},{"key":"1382_CR28","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1172\/JCI78085","volume":"125","author":"PR Burkett","year":"2015","unstructured":"Burkett PR, zu Horste GM, Kuchroo VK. Pouring fuel on the fire: Th17 cells, the environment, and autoimmunity. J Clin Investig. 2015;125:2211\u20139.","journal-title":"J Clin Investig"},{"key":"1382_CR29","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.immuni.2014.10.004","volume":"41","author":"ST Crotty","year":"2014","unstructured":"Crotty ST. Follicular helper cell differentiation, function, and roles in disease. Immunity. 2014;41:529\u201342.","journal-title":"Immunity"},{"key":"1382_CR30","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.it.2013.10.004","volume":"35","author":"E Schmitt","year":"2014","unstructured":"Schmitt E, Klein M, Bopp T. Th9 cells, new players in adaptive immunity. Trends Immunol. 2014;35:61\u20138.","journal-title":"Trends Immunol"},{"key":"1382_CR31","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3389\/fimmu.2012.00178","volume":"3","author":"JB Wing","year":"2012","unstructured":"Wing JB, Sakaguchi S. Multiple Treg suppressive modules and their adaptability. Front Immunol. 2012;3:178.","journal-title":"Front Immunol"},{"key":"1382_CR32","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/nri.2015.18","volume":"16","author":"M DuPage","year":"2016","unstructured":"DuPage M, Bluestone JA. Harnessing the plasticity of CD4(+) T cells to treat immune-mediated disease. Nat Rev Immunol. 2016;16:149\u201363.","journal-title":"Nat Rev Immunol"},{"key":"1382_CR33","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1126\/science.1178334","volume":"327","author":"JJ O'Shea","year":"2010","unstructured":"O\u2019Shea JJ, Paul WE. Mechanisms underlying lineage commitment and plasticity of helper CD4(+) T cells. Science. 2010;327:1098\u2013102.","journal-title":"Science"},{"key":"1382_CR34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.jaut.2017.12.003","volume":"87","author":"T Agalioti","year":"2018","unstructured":"Agalioti T, Villablanca EJ, Huber S, Gagliani N. TH17 cell plasticity: the role of dendritic cells and molecular mechanisms. J Autoimmun. 2018;87:50\u201360.","journal-title":"J Autoimmun"},{"key":"1382_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2023.102333","volume":"83","author":"T Agalioti","year":"2023","unstructured":"Agalioti T, Cortesi F, Gagliani N. TH17 cell immune adaptation. Currt Opin Immunol. 2023;83: 102333.","journal-title":"Currt Opin Immunol"},{"key":"1382_CR36","doi-asserted-by":"publisher","first-page":"7061","DOI":"10.1073\/pnas.1415675112","volume":"112","author":"SN Harbour","year":"2015","unstructured":"Harbour SN, Maynard CL, Zindl CL, et al. Th17 cells give rise to Th1 cells that are required for the pathogenesis of colitis. Proc Natl Acad Sci (USA). 2015;112:7061\u20136.","journal-title":"Proc Natl Acad Sci (USA)"},{"key":"1382_CR37","doi-asserted-by":"publisher","first-page":"2340","DOI":"10.1182\/blood-2008-01-133967","volume":"112","author":"HJ Koenen","year":"2008","unstructured":"Koenen HJ, Smeets RL, Vink PM, et al. Human CD25(high) Foxp3(pos) regulatory T cells differentiate into IL-17-producing cells. Blood. 2008;112:2340\u201352.","journal-title":"Blood"},{"key":"1382_CR38","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.immuni.2008.05.007","volume":"29","author":"XO Yang","year":"2008","unstructured":"Yang XO, Nurieva R, Martinez GJ, et al. Molecular antagonism and plasticity of regulatory and inflammatory T cell programs. Immunity. 2008;29:44\u201356.","journal-title":"Immunity"},{"key":"1382_CR39","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1038\/nature14452","volume":"523","author":"N Gagliani","year":"2015","unstructured":"Gagliani N, Vesely MCA, Iseppon A, et al. Th17 cells transdifferentiate into regulatory T cells during resolution of inflammation. Nature. 2015;523:221\u20135.","journal-title":"Nature"},{"key":"1382_CR40","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1016\/j.jaci.2014.05.038","volume":"134","author":"C Irvin","year":"2014","unstructured":"Irvin C, Zafar I, Good J, et al. Increased frequency of dual-positive TH2\/TH17 cells in bronchoalveolar lavage fluid characterizes a population of patients with severe asthma. J Allergy Clin Immunol. 2014;134:1175-86.e7.","journal-title":"J Allergy Clin Immunol"},{"key":"1382_CR41","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.jaci.2009.10.012","volume":"125","author":"L Cosmi","year":"2010","unstructured":"Cosmi L, Maggi L, Santarlasci V, et al. Identification of a novel subset of human circulating memory CD4(+) T cells that produce both IL-17A and IL-4. J Allergy Clin Immunol. 2010;125:222-30.e1-4.","journal-title":"J Allergy Clin Immunol"},{"key":"1382_CR42","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1016\/j.jaci.2022.04.027","volume":"150","author":"D McCluskey","year":"2022","unstructured":"McCluskey D, Benzian-Olsson N, Mahil SK, et al. Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. J Allergy Clin Immunol. 2022;150:882\u201393.","journal-title":"J Allergy Clin Immunol"},{"key":"1382_CR43","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1016\/j.jid.2020.09.028","volume":"141","author":"K Kobayashi","year":"2021","unstructured":"Kobayashi K, Kamekura R, Kato J, et al. Cigarette smoke underlies the pathogenesis of palmoplantar pustulosis via an IL-17A-induced production of IL-36\u03b3 in tonsillar epithelial cells. J Investig Dermatol. 2021;141:1533-41.e4.","journal-title":"J Investig Dermatol"},{"key":"1382_CR44","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00403-010-1112-x","volume":"303","author":"K Torii","year":"2011","unstructured":"Torii K, Furuhashi T, Saito C, et al. Increased peripheral Th17 in patients with pustulosis palmaris et plantaris. Arch Dermatol Res. 2011;303:441\u20134.","journal-title":"Arch Dermatol Res"},{"key":"1382_CR45","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1186\/s12890-019-0899-2","volume":"19","author":"W Xu","year":"2019","unstructured":"Xu W, Li R, Sun Y. Increased IFN-\u03b3-producing Th17\/Th1 cells and their association with lung function and current smoking status in patients with chronic obstructive pulmonary disease. BMC Pulm Med. 2019;19:137.","journal-title":"BMC Pulm Med"},{"key":"1382_CR46","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/j.jaad.2005.07.024","volume":"54","author":"G Micha\u00eblsson","year":"2006","unstructured":"Micha\u00eblsson G, Gustafsson K, Hagforsen E. The psoriasis variant palmoplantar pustulosis can be improved after cessation of smoking. J Am Acad Dermatol. 2006;54:737\u20138.","journal-title":"J Am Acad Dermatol"},{"key":"1382_CR47","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1111\/bjd.16560","volume":"179","author":"K Yan","year":"2018","unstructured":"Yan K, Xu W, Huang Y, et al. Methotrexate restores the function of peripheral blood regulatory T cells in psoriasis vulgaris via the CD73\/AMPK\/mTOR pathway. Br J Dermatol. 2018;179:896\u2013905.","journal-title":"Br J Dermatol"},{"key":"1382_CR48","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/bjd.19380","volume":"184","author":"L Nussbaum","year":"2021","unstructured":"Nussbaum L, Chen YL, Ogg GS. Role of regulatory T cells in psoriasis pathogenesis and treatment. Br J Dermatol. 2021;184:14\u201324.","journal-title":"Br J Dermatol"},{"key":"1382_CR49","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1016\/j.celrep.2018.12.012","volume":"25","author":"T Hartwig","year":"2018","unstructured":"Hartwig T, Zwicky P, Schreiner B, et al. Regulatory T cells restrain pathogenic T helper cells during skin inflammation. Cell Rep. 2018;25:3564-72.e4.","journal-title":"Cell Rep"},{"key":"1382_CR50","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1084\/jem.20172094","volume":"215","author":"K Stockenhuber","year":"2018","unstructured":"Stockenhuber K, Hegazy AN, West NR, et al. Foxp3(+) T reg cells control psoriasiform inflammation by restraining an IFN-I-driven CD8(+) T cell response. J Exp Med. 2018;215:1987\u201398.","journal-title":"J Exp Med"},{"key":"1382_CR51","doi-asserted-by":"publisher","first-page":"2275","DOI":"10.1126\/science.1074129","volume":"297","author":"L Shan","year":"2002","unstructured":"Shan L, Molberg O, Parrot I, et al. Structural basis for gluten intolerance in celiac sprue. Science. 2002;297:2275\u20139.","journal-title":"Science"},{"key":"1382_CR52","doi-asserted-by":"publisher","first-page":"1020977","DOI":"10.3389\/fmicb.2022.1020977","volume":"13","author":"T Shi","year":"2022","unstructured":"Shi T, Feng Y, Liu W, et al. Characteristics of gut microbiota and fecal metabolomes in patients with celiac disease in northwest China. Front Microbiol. 2022;13:1020977.","journal-title":"Front Microbiol"},{"key":"1382_CR53","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12916-019-1380-z","volume":"17","author":"G Caio","year":"2019","unstructured":"Caio G, Volta U, Sapone A, et al. Celiac disease: a comprehensive current review. BMC Med. 2019;17:142.","journal-title":"BMC Med"},{"key":"1382_CR54","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.immuni.2016.10.020","volume":"45","author":"CF Krebs","year":"2016","unstructured":"Krebs CF, Paust HJ, Krohn S, et al. Autoimmune renal disease Is exacerbated by S1P-receptor-1-dependent intestinal Th17 cell migration to the kidney. Immunity. 2016;45:1078\u201392.","journal-title":"Immunity"},{"key":"1382_CR55","doi-asserted-by":"publisher","first-page":"294","DOI":"10.3390\/biomedicines11020294","volume":"11","author":"C Campbell","year":"2023","unstructured":"Campbell C, Kandalgaonkar MR, Golonka RM, et al. Crosstalk between gut microbiota and host immunity: impact on inflammation and immunotherapy. Biomedicines. 2023;11:294.","journal-title":"Biomedicines"},{"key":"1382_CR56","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.immuni.2010.06.001","volume":"32","author":"HJ Wu","year":"2010","unstructured":"Wu HJ, Ivanov II, Darce J, et al. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity. 2010;32:815\u201327.","journal-title":"Immunity"},{"key":"1382_CR57","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.cell.2020.05.048","volume":"182","author":"S Kitamoto","year":"2020","unstructured":"Kitamoto S, Nagao-Kitamoto H, Jiao Y, et al. The intermucosal connection between the mouth and gut in commensal pathobiont-driven colitis. Cell. 2020;182:447-62.e14.","journal-title":"Cell"},{"key":"1382_CR58","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/1346-8138.15100","volume":"46","author":"Y Harabuchi","year":"2019","unstructured":"Harabuchi Y, Takahara M. Pathogenic role of palatine tonsils in palmoplantar pustulosis: a review. J Dermatol. 2019;46:931\u20139.","journal-title":"J Dermatol"},{"key":"1382_CR59","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1111\/1346-8138.16132","volume":"48","author":"Y Okubo","year":"2021","unstructured":"Okubo Y, Morishima H, Zheng R, Terui T. Sustained efficacy and safety of guselkumab in patients with palmoplantar pustulosis through 1.5 years in a randomized phase 3 study. J Dermatol. 2021;48:1838\u201353.","journal-title":"J Dermatol"},{"key":"1382_CR60","doi-asserted-by":"publisher","DOI":"10.5826\/dpc.1302a97","volume":"13","author":"L Gargiulo","year":"2023","unstructured":"Gargiulo L, et al. Risankizumab for the treatment of palmoplantar pustular psoriasis: a report of two cases. Dermatol Pract Concept. 2023;13: e2023097.","journal-title":"Dermatol Pract Concept"},{"key":"1382_CR61","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.1016\/j.bcp.2012.01.001","volume":"83","author":"P Schafer","year":"2012","unstructured":"Schafer P. Apremilast mechanism of action and application to psoriasis and psoriatic arthritis. Biochem Pharmacol. 2012;83:1583\u201390.","journal-title":"Biochem Pharmacol"},{"key":"1382_CR62","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1007\/s40257-020-00503-5","volume":"21","author":"M Misiak-Galazka","year":"2022","unstructured":"Misiak-Galazka M, Zozula J, Rudnicka L. Palmoplantar pustulosis: Recent advances in etiopathogenesis and emerging treatments. Am J Clin Dermatol. 2022;21:355\u201370.","journal-title":"Am J Clin Dermatol"},{"key":"1382_CR63","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/1523-1747.ep12472344","volume":"100","author":"SC Chan","year":"1993","unstructured":"Chan SC, Li SH, Hanifin JM. Increased interleukin-4 production by atopic mononuclear leukocytes correlates with increased cyclic adenosine monophosphate-phosphodiesterase activity and is reversible by phosphodiesterase inhibition. J Investig Dermatol. 1993;100:681\u20134.","journal-title":"J Investig Dermatol"},{"key":"1382_CR64","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/1523-1747.ep12297888","volume":"107","author":"JM Hanifin","year":"1996","unstructured":"Hanifin JM, Chan SC, Cheng JB, et al. Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. J Investig Dermatol. 1996;107:51\u20136.","journal-title":"J Investig Dermatol"},{"key":"1382_CR65","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1001\/jamadermatol.2019.0008","volume":"155","author":"H Yang","year":"2019","unstructured":"Yang H, Wang J, Zhang X, et al. Application of topical phosphodiesterase 4 inhibitors in mild to moderate atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2019;155:585\u201393.","journal-title":"JAMA Dermatol"},{"issue":"1_suppl","key":"1382_CR66","doi-asserted-by":"publisher","first-page":"3S","DOI":"10.1177\/12034754221141680","volume":"27","author":"WJ Loo","year":"2023","unstructured":"Loo WJ, Turchin I, Prajapati VH, et al. Clinical implications of targeting the JAK\u2013STAT pathway in psoriatic disease: emphasis on the TYK2 pathway. J Cutan Med Surg. 2023;27(1_suppl):3S-24S.","journal-title":"J Cutan Med Surg"},{"key":"1382_CR67","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1016\/j.jaci.2024.07.017","volume":"154","author":"KR van Straalen","year":"2024","unstructured":"van Straalen KR, Kirma J, Yee CM, et al. Disease heterogeneity and molecular classification of inflammatory palmoplantar diseases. J Allergy Clin Immunol. 2024;154:1204-1215.e9.","journal-title":"J Allergy Clin Immunol"},{"key":"1382_CR68","volume":"35","author":"Y-X Zheng","year":"2022","unstructured":"Zheng Y-X, Zheng M, Cai S-Q. Successful treatment of secukinumab-resistant palmoplantar pustulosis by Dupilumab: a case report. Dermatol Ther (Heidelb). 2022;35: e15781.","journal-title":"Dermatol Ther (Heidelb)"},{"key":"1382_CR69","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1038\/mi.2014.134","volume":"8","author":"AT Cao","year":"2015","unstructured":"Cao AT, Yao S, Gong B, et al. Interleukin (IL)-21 promotes intestinal IgA response to microbiota. Mucosal Immunol. 2015;8:1072\u201382.","journal-title":"Mucosal Immunol"},{"key":"1382_CR70","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/1523-1747.ep12560807","volume":"90","author":"T Okada","year":"1988","unstructured":"Okada T, Konishi H, Ito M, et al. Identification of secretory immunoglobulin A in human sweat and sweat glands. J Investig Dermatol. 1988;90:648\u201351.","journal-title":"J Investig Dermatol"},{"key":"1382_CR71","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1111\/1523-1747.ep12709634","volume":"92","author":"Y Terui","year":"1989","unstructured":"Terui Y, Kato T, Tagami H. Stratum corneum activation of complement through the antibody-independent alternative pathway. J Investig Dermatol. 1989;92:593\u20137.","journal-title":"J Investig Dermatol"},{"key":"1382_CR72","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1159\/000087019","volume":"211","author":"M Ozawa","year":"2005","unstructured":"Ozawa M, Terui T, Tagami H. Localization of IL-8 and complement components in lesional skin of psoriasis vulgaris and pustulosis palmaris et plantaris. Dermatology. 2005;211:249\u201355.","journal-title":"Dermatology"},{"key":"1382_CR73","doi-asserted-by":"publisher","first-page":"6092","DOI":"10.4049\/jimmunol.175.9.6092","volume":"175","author":"LH Ulfman","year":"2005","unstructured":"Ulfman LH, Alblas J, van Aalst CW, et al. Differences in potency of CXC chemokine ligand 8-, CC chemokine ligand 11-, and C5a-induced modulation of integrin function on human eosinophils. J Immunol. 2005;175:6092\u20139.","journal-title":"J Immunol"},{"key":"1382_CR74","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1159\/000247468","volume":"185","author":"H Aoyama","year":"1992","unstructured":"Aoyama H, Tagami H. Eosinophilic pustular folliculitis starting initially only with palmoplantar pustular lesions. Report of a case and review of the literature. Dermatology. 1992;185:276\u201380.","journal-title":"Dermatology"},{"key":"1382_CR75","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1111\/1346-8138.15503","volume":"47","author":"N Umegaki-Arao","year":"2020","unstructured":"Umegaki-Arao N, Tanemoto S, Tanese K, et al. Eosinophilic pustular folliculitis with palmoplantar lesions and nail deformity. J Dermatol. 2020;47:e357\u20139.","journal-title":"J Dermatol"},{"key":"1382_CR76","doi-asserted-by":"publisher","first-page":"12269","DOI":"10.1073\/pnas.1918196117","volume":"117","author":"I Morianos","year":"2020","unstructured":"Morianos I, Trochoutsou AI, Papadopoulou G, et al. Activin-A limits Th17 pathogenicity and autoimmune neuroinflammation via CD39 and CD73 ectonucleotidases and Hif1-\u03b1\u2013dependent pathways. Proc Natl Acad Sci (USA). 2020;117:12269\u201380.","journal-title":"Proc Natl Acad Sci (USA)"},{"key":"1382_CR77","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1038\/s41467-020-17097-5","volume":"11","author":"H Xu","year":"2020","unstructured":"Xu H, Agalioti T, Zhao J, et al. The induction and function of the anti-inflammatory fate of TH17 cells. Nat Commun. 2020;11:3334.","journal-title":"Nat Commun"}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-025-01382-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-025-01382-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,6]],"date-time":"2025-04-06T03:58:41Z","timestamp":1743911921000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-025-01382-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,15]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["1382"],"URL":"https:\/\/doi.org\/10.1007\/s13555-025-01382-6","relation":{},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,15]]},"assertion":[{"value":"7 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Tadashi Terui has received research funds from Maruho Co., Ltd., and honoraria for a speaker, consultancy, and advisory board member from AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen Pharmaceuticals, Inc., Kyowa Kirin Pharma, Inc., Mitsubishi Tanabe Pharma Co., Novartis, Sanofi, Taiho Pharmaceutical Co., Ltd., UCB Japan. Masamoto Murakami has received research funds from AbbVie and honoraria for a speaker, consultancy, and advisory board member from, Amgen Inc., Boehringer Ingelheim, Bristol Myers Squibb, Janssen Pharmaceuticals, Inc, Kyowa Kirin Pharma, Inc., Taiho Pharmaceutical Co., Ltd., UCB Japan. Yukari Okubo has received research funds from AbbVie, Eisai, Torii Pharmaceutical Co., Ltd., Maruho Co., Ltd., Shiseido, Sun Pharma. Honoraria for a speaker, consultancy, and advisory board member from AbbVie, Amgen Inc., Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Janssen Pharmaceuticals, Inc., Kyowa Kirin Pharma, Inc., LEO Pharma, Maruho Co. Ltd., Novartis Pharma, Pfizer, Sanofi, Sun Pharma, Taiho Pharmaceutical Co., Ltd., UCB Japan Pharma, and honoraria for a speaker from Eisai, Jimro, Mitsubishi Tanabe Pharma Co., Torii Pharmaceutical Co., Ltd. Koremasa Hayama has received research funds and honoraria for a speaker from Maruho Co. Ltd, Taiho Pharmaceutical Co., Ltd., and Torii Pharmaceutical Co., Ltd., and honoraria for a speaker, consultancy, and advisory from AbbVie, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc, Novartis, Sanofi, UCB Japan, and honoraria for a speaker from Daiichi Sankyo Co. Ltd, Eli Lilly, Kyowa Kirin Pharma, Inc., Mitsubishi Tanabe Pharma Co., Hideki Fujita has received research grant or honoraria for speaker and\/or consultancy from AbbVie, Amgen, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi-Sanyo, Eisai, Eli Lilly, Janssen, JMEC, Kaken, Kyowa Kirin, LEO, Maruho, Mitsubishi Tanabe, Nihon Pharma, Novartis, Otsuka, Sanofi, Sun Pharma, Taiho, Torii, Towa, UCB, and Ushio.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}